CD19-CAR T cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes)

CD19 CAR T cells engineered with CD28-CD3zeta signaling and EGFRt safety switch in naive/memory T lymphocytes

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19-CAR T cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes), covering 2025-07-08 to 2025-07-08. Get the full timeline:

Most recent: Clinical Trial Update: Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma [Phase 1]

See pricing